Download full-text PDF |
Source |
---|
J Clin Med
July 2020
Department of Clinical Haematology, CHU Montpellier, 34295 Montpellier, France.
Donor lymphocyte infusion (DLI) is used to prevent or treat haematological malignancies relapse after allogeneic stem cell transplantation (allo-SCT). Recombinant human granulocyte colony-stimulated factor primed DLI (gDLI) is derived from frozen aliquots of the peripheral blood stem cell collection. We compared the efficacy and safety of gDLI and classical DLI after allo-SCT.
View Article and Find Full Text PDFStrahlenther Onkol
April 2011
Department of Radiation Oncology, University of Cologne, Cologne, Germany.
Purpose: Since the 20(th) century, radiotherapy (RT) has been used for treatment of symptomatic splenomegaly (SM). SM occurs in association with hematologic disorders. The purpose of this analysis was to determine the indication, treatment concepts, and efficiency of RT.
View Article and Find Full Text PDFTranspl Infect Dis
June 2010
Department of Medicine, Division of Hematology/Oncology, University of Rostock, Rostock, Germany.
Invasive mold infections are a threat to immunosuppressed patients such as patients with graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT). Up to 10% of SCT recipients develop invasive aspergillosis (IA). Invasive zygomycosis (IZ) may occur during treatment against IA.
View Article and Find Full Text PDFRadiol Clin North Am
July 2008
Department of Clinical Radiology, University of Munich, Grosshadern, Germany.
Multiple myeloma is a hemato-oncologic disease in the elderly population, with a peak incidence in the eighth decade, and represents a malignant bone marrow neoplasia in which a monoclonal strain of atypical plasma cells proliferates and may result in bone destruction. Skeletal metastases represent the most common malignant bone tumor and are the third most common location for distant metastases. They occur predominantly in adults, especially in the elderly population.
View Article and Find Full Text PDFLeuk Lymphoma
March 2006
First Medical Department with Medical Oncology, Wilhelminen Hospital, Vienna, Austria.
The course of disease in patients with myelofibrosis is highly variable, with survival ranging from few months to many years. Several prognostic models have been established, with the LILLE score now most commonly used. However, in recent series, the latter scoring system repeatedly failed to discriminate patients with intermediate and poor prognosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!